PMID- 21860549
OWN - NLM
STAT- MEDLINE
DCOM- 20111212
LR  - 20211020
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Print)
IS  - 1011-8934 (Linking)
VI  - 26
IP  - 8
DP  - 2011 Aug
TI  - Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ 
      hybridization in invasive breast cancer: a single institution study.
PG  - 1001-6
LID - 10.3346/jkms.2011.26.8.1001 [doi]
AB  - This study aimed to determine the incidence and characteristics of HER-2 gene 
      heterogeneity in invasive breast cancer in a single institution. Included were 
      971 cases of primary invasive breast cancer diagnosed between 2008 and 2010. 
      Fluorescence in situ hybridization (FISH) image files were retrospectively 
      reviewed and HER-2 gene heterogeneity was defined as more than 5% but less than 
      50% of analyzed invasive tumor cells with a HER-2/Chr17 ratio higher than 2.2, 
      according to the College of American Pathologists guidelines. HER-2 gene 
      heterogeneity was identified in 24 (2.5%) cases. The mean proportion of invasive 
      tumor cells with a HER-2/chromosome 17 ratio higher than 2.2 was 11.6% (range: 
      5%-25%). Of 24 cases, HER-2 gene status was not amplified in 8, showed borderline 
      amplification in 2, and amplification in 14. All HER-2 amplification cases were 
      low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is 
      identified in routine FISH examination. This may affect the results of HER-2 gene 
      amplification status in FISH studies.
FAU - Lee, Sarah
AU  - Lee S
AD  - Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
FAU - Jung, Woohee
AU  - Jung W
FAU - Hong, Soon-Won
AU  - Hong SW
FAU - Koo, Ja Seung
AU  - Koo JS
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20110727
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Breast Neoplasms/*genetics/pathology
MH  - Chromosomes, Human, Pair 17
MH  - Female
MH  - Genetic Heterogeneity
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Middle Aged
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Retrospective Studies
PMC - PMC3154334
OTO - NOTNLM
OT  - Breast Neoplasms
OT  - Gene Heterogeneity
OT  - HER-2
OT  - In Situ Hybridization, Fluorescence
EDAT- 2011/08/24 06:00
MHDA- 2011/12/14 06:00
PMCR- 2011/08/01
CRDT- 2011/08/24 06:00
PHST- 2011/03/03 00:00 [received]
PHST- 2011/05/17 00:00 [accepted]
PHST- 2011/08/24 06:00 [entrez]
PHST- 2011/08/24 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
PHST- 2011/08/01 00:00 [pmc-release]
AID - 10.3346/jkms.2011.26.8.1001 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2011 Aug;26(8):1001-6. doi: 10.3346/jkms.2011.26.8.1001. Epub 
      2011 Jul 27.